反式-N3P3Az2(NHMe)4（AZP）在非小细胞肺癌中的II期评估
Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
作者信息
Postmus P E, Mulder N H, Grampel J C, Meyers W H, Berendsen H H
机构信息
Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.
出版信息
Eur J Cancer Clin Oncol. 1987 Aug;23(8):1207-8. doi: 10.1016/0277-5379(87)90156-8.
PMID:2820748
Abstract
Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.
摘要
反式-N3P3Az2(NHMe)4（AZP），一种氮丙啶基取代的环磷腈，在一项非小细胞肺癌的II期研究中进行了评估，剂量为每3周静脉推注0.33 mg/m²。未观察到肿瘤反应。注意到其累积骨髓毒性与其他环磷腈相当。AZP对非小细胞肺癌的治疗无效。
相似文献
1
Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
Eur J Cancer Clin Oncol. 1987 Aug;23(8):1207-8. doi: 10.1016/0277-5379(87)90156-8.
2
Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4.
Cancer Treat Rep. 1987 Feb;71(2):155-9.
3
Phase II clinical evaluation of AZQ in renal cell carcinoma.
Am J Clin Oncol. 1986 Apr;9(2):126-8. doi: 10.1097/00000421-198604000-00004.
4
Phase II study of diaziquone in patients with advanced carcinoma of the lung.
Cancer Treat Rep. 1984 Sep;68(9):1193-4.
5
Phase II clinical trial of diaziquone in bronchogenic carcinoma.
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):921-2.
6
Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
Am J Clin Oncol. 1984 Aug;7(4):353-5. doi: 10.1097/00000421-198408000-00011.
7
Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
Eur J Cancer Clin Oncol. 1983 Feb;19(2):295-8. doi: 10.1016/0277-5379(83)90430-3.
8
Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Am J Clin Oncol. 1983 Apr;6(2):171-3. doi: 10.1097/00000421-198304000-00005.
9
Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
Cancer Treat Rep. 1982 Jun;66(6):1321-5.
10
Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
Am J Clin Oncol. 1988 Aug;11(4):474-8. doi: 10.1097/00000421-198808000-00013.
Zotero 插件